Relugolix for the treatment of uterine fibroids

References

• Bulun SE. Uterine fibroids. N Engl J Med. 2013;369(14):1344–1355.
   PubMed Web of Science ®Google Scholar
• Donnez J, Courtoy GE, Dolmans MM. Fibroid management in premenopausal women. Climacteric. 2019;22(1):27–33.
   PubMed Web of Science ®Google Scholar
• Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003 Jan;188(1):100–107. .
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22(6):665–686.
   PubMed Web of Science ®Google Scholar
• Lumsden MA, Hamoodi I, Gupta J, et al. Fibroids: diagnosis and management. BMJ. 2015;351:h488.
   Google Scholar
• Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med. 2015;372(17):1646–1655.
   PubMed Web of Science ®Google Scholar
• Gupta S, Jose J, Manyonda I. Clinical presentation of fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):615–626.
   PubMed Web of Science ®Google Scholar
• Ghant MS, Sengoba KS, Recht H, et al. Beyond the physical: a qualitative assessment of the burden of symptomatic uterine fibroids on women’s emotional and psychosocial health. J Psychosom Res. 2015;78(5):499–503.
   PubMed Web of Science ®Google Scholar
• Dolmans MM, Donnez J, Fellah L. Uterine fibroid management: today and tomorrow. J Obstet Gynaecol Res. 2019;45(7):1222–1229.
   PubMed Web of Science ®Google Scholar
• Cardozo ER, Clark AD, Banks NK, et al. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012;206(3):211.
   PubMed Web of Science ®Google Scholar
• Ciarmela P, Islam MS, Reis FM, et al. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update. 2011;17(6):772‐790.
   PubMed Web of Science ®Google Scholar
• Mäkinen N, Mehine M, Tolvanen J, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334(6053):252‐255.
   PubMed Web of Science ®Google Scholar
• Styer AK, Rueda BR. The epidemiology and genetics of uterine leiomyoma. Best Pract Res Clin Obstet Gynaecol. 2016;34:3–12.
   PubMed Web of Science ®Google Scholar
• Stewart EA, Cookson CL, Gandolfo RA, et al. Epidemiology of uterine fibroids: a systematic review. BJOG. 2015;372(17):1501‐1512.
   Google Scholar
• Walker CL, Cesen-Cummings K, Houle C, et al. Protective effect of pregnancy for development of uterine leiomyoma. Carcinogenesis. 2001 Dec;22(12):2049–2052.
   PubMed Web of Science ®Google Scholar
• Islam MS, Protic O, Stortoni P, et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil Steril. 2013b;100(1):178–193.
   PubMed Web of Science ®Google Scholar
• Ciebiera M, Włodarczyk M, Słabuszewska-Jóźwiak a, et al. Influence of vitamin D and transforming growth factor β3 serum concentrations, obesity, and family history on the risk for uterine fibroids. Fertil Steril. 2016;106(7):1787‐1792.
   PubMed Web of Science ®Google Scholar
• Al-Hendy a, Myers ER, Stewart E. Uterine fibroids: burden and Unmet Medical Need. Semin Reprod Med. 2017;35(6):473–480.
   PubMed Web of Science ®Google Scholar
• Mehta a, Xu T, Hutfless S, et al. Patient, surgeon, and hospital disparities associated with benign hysterectomy approach and perioperative complications. Am J Obstet Gynecol. 2017;216:497.
   PubMed Web of Science ®Google Scholar
• Segars JH, Al-Hendy a. Uterine leiomyoma: new perspectives on an old disease. Semin Reprod Med. 2017 Nov;35(6):471–472.
   PubMed Web of Science ®Google Scholar
• Venturella R, Lico D, Sarica a, et al. OvAge: a new methodology to quantify ovarian reserve combining clinical, biochemical and 3D-ultrasonographic parameters. J Ovarian Res. 2015;8(1):21.
   PubMedGoogle Scholar
• Guarnaccia MM, Rein MS. Traditional surgical approaches to uterine fibroids: abdominal myomec- tomy and hysterectomy. Clin Obstet Gynecol. 2001;44(2):385–400.
   PubMed Web of Science ®Google Scholar
• Barra F, Seca M, Della Corte L, et al. Relugolix for the treatment of uterine fibroids. Drugs Today (Barc). 2019;55(8):503–512.
   PubMed Web of Science ®Google Scholar
• Gupta JK, Sinha a, Lumsden MA, et al. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev. 2012;5:CD005073.
   PubMed Web of Science ®Google Scholar
• Spies JB. Current role of uterine artery embolization in the management of uterine fibroids. Clin Obstet Gynecol. 2016;59(1):93–102.
   PubMed Web of Science ®Google Scholar
• Goodwin SC, Spies JB. Uterine fibroid embolization. N Engl J Med. 2009;361(7):690–697.
   PubMed Web of Science ®Google Scholar
• Clark NA, Mumford SL, Segars JH. Reproductive impact of MRI-guided focused ultrasound surgery for fibroids: a systematic review of the evidence. Curr Opin Obstet Gynecol. 2014;26(3):151–161.
   PubMed Web of Science ®Google Scholar
• Łoziński T, Filipowska J, Gurynowicz G, et al. The effect of high-intensity focused ultrasound guided by magnetic resonance therapy on obstetrical outcomes in patients with uterine fibroids – experiences from the main Polish center and a review of current data. Int J Hyperthermia. 2019;36(1):582–590.
   PubMed Web of Science ®Google Scholar
• Zupi E, Centini G, Sabbioni L, et al. Nonsurgical alternatives for uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2016;34:122–131.
   PubMed Web of Science ®Google Scholar
• National Institute for Health Care and Excellence. Heavy menstrual bleeding: assessment and management (NG88). Updated November 2018. [ cited 2019 Dec 4]. Available from: https://www.nice.org.uk/guidance/ng88/resources/heavy-menstrual-bleeding-assessment-and-management-pdf- 1837701412549
   Google Scholar
• Chwalisz K, Taylor H. Current and emerging medical treatments for uterine fibroids. Semin Reprod Med. 2017;35(6):510–522.
   PubMed Web of Science ®Google Scholar
• Lethaby a, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev. 2017;11(11):CD000547.
   Google Scholar
• Kessel B, Dahl KD, Kazer RR, et al. The dependency of bioactive follicle-stimulating hormone secretion on gonadotropin-releasing hormone in hypogonadal and cycling women. J Clin Endocrinol Metab. 1988;66(2):361–366.
   PubMed Web of Science ®Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012a;366(5):409–420.
   PubMed Web of Science ®Google Scholar
• Donnez J, Tomaszewski J, Vázquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012b;366(5):421–432.
   PubMed Web of Science ®Google Scholar
• Donnez J, Vázquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101(6):1565–73.e1-18.
   Web of Science ®Google Scholar
• Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103(2):519–27.e3.
   PubMed Web of Science ®Google Scholar
• Mahase E. Uterine fibroid drug is recalled after case of liver failure requiring transplant prompts EU review. BMJ. 2020;368. 10.1136/bmj.l6968
   Google Scholar
• Islam S, Afrin S, Jones SI, et al. Selective progesterone receptor modulators-mechanisms and therapeutic utility. Endocr Rev. 2020;41(5):bnaa012.
   PubMed Web of Science ®Google Scholar
• Broekmans FJ. GnRH agonists and uterine leiomyomas. Hum Reprod. 1996;11(Suppl 3):3–25.
   PubMedGoogle Scholar
• Lamb YN. Elagolix: first global approval. Drugs. 2018 Sep;78(14):1501–1508.
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Ackerman RT, Al-Hendy a, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328‐340.
   Web of Science ®Google Scholar
• Markham a. Relugolix: first global approval. Drugs. 2019;79(6):675–679.
   PubMed Web of Science ®Google Scholar
• Hara T, Araki H, Kusaka M, et al. Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys. J Clin Endocrinol Metab. 2003;88(4):1697–1704.
   PubMed Web of Science ®Google Scholar
• Miwa K, Hitaka T, Imada T, et al. Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino) methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl] phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2011;54(14):4998–5012.
   PubMed Web of Science ®Google Scholar
• Nakata D, Masaki T, Tanaka a, et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014;723:167–174.
   PubMed Web of Science ®Google Scholar
• Hoshiai H, Seki Y, Kusumoto T, et al. Phase 2 study of relugolix vs placebo in heavy menstrual bleeding associated with uterine fibroids [17H]. Obstet Gynecol. 2017;129:86S.
   Web of Science ®Google Scholar
• Osuga Y, Enya K, Kudou K, et al. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2019a;133(3):423–433.
   PubMed Web of Science ®Google Scholar
• Osuga Y, Enya K, Kudou K, et al. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril. 2019b Oct 6;S0015-0282(19): 30618–1.
   Google Scholar
• Tarlatzis BC, Kolibianakis EM. GnRH agonists vs antagonists. Best Pract Res Clin Obstet Gynaecol. 2007;21(1):57‐65.
   PubMed Web of Science ®Google Scholar
• Bartels CB, Cayton KC, Chuong FS, et al. An evidence-based approach to the medical management of fibroids: a systematic review. Clin Obstet Gynecol. 2016;59(1):30‐52.
   PubMed Web of Science ®Google Scholar
• Schultze-Mosgau a, Griesinger G, Altgassen C, et al. New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists. Expert Opin Investig Drugs. 2005;14(9):1085–1097.
   PubMed Web of Science ®Google Scholar